Compare IPHA & III Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IPHA | III |
|---|---|---|
| Founded | 1999 | 2006 |
| Country | France | United States |
| Employees | N/A | 1500 |
| Industry | Biotechnology: Pharmaceutical Preparations | Professional Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 165.3M | 197.1M |
| IPO Year | 2014 | 2006 |
| Metric | IPHA | III |
|---|---|---|
| Price | $1.84 | $5.30 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 1 |
| Target Price | ★ $5.75 | $5.50 |
| AVG Volume (30 Days) | 33.6K | ★ 166.1K |
| Earning Date | 03-26-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 4.46% |
| EPS Growth | N/A | ★ 216.67 |
| EPS | N/A | ★ 0.12 |
| Revenue | N/A | ★ $192,745,000.00 |
| Revenue This Year | $180.36 | $3.85 |
| Revenue Next Year | N/A | $4.34 |
| P/E Ratio | ★ N/A | $43.17 |
| Revenue Growth | N/A | ★ 4.51 |
| 52 Week Low | $1.18 | $3.74 |
| 52 Week High | $2.71 | $6.45 |
| Indicator | IPHA | III |
|---|---|---|
| Relative Strength Index (RSI) | 40.56 | 61.47 |
| Support Level | $1.67 | $3.86 |
| Resistance Level | $1.88 | $5.36 |
| Average True Range (ATR) | 0.11 | 0.14 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 9.09 | 67.02 |
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.
Information Services Group Inc is an AI-centered technology research and advisory firm providing digital transformation and technology advisory services that help organizations optimize performance, reduce costs, and accelerate innovation. The Company's expertise includes sourcing advisory, cloud and data analytics, managed governance and risk services, network and software advisory, technology strategy and operations design, change management, and market intelligence, serving both private- and public-sector clients globally. It operates in one segment, fact-based sourcing advisory services, and operates principally in the Americas, with generate maximum revenue in Europe and the Asia Pacific.